NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free IOBT Stock Alerts $1.44 -0.04 (-2.70%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.41▼$1.5550-Day Range$1.47▼$1.8252-Week Range$0.82▼$2.64Volume78,243 shsAverage Volume91,550 shsMarket Capitalization$94.87 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get IO Biotech alerts: Email Address IO Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside478.7% Upside$8.33 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$988,214 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.41) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 starsMedical Sector293rd out of 910 stocksPharmaceutical Preparations Industry126th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIO Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently decreased by 16.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 2.0 News and Social Media Coverage News SentimentIO Biotech has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for IO Biotech this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $988,214.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of IO Biotech is held by insiders.Percentage Held by Institutions54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to grow in the coming year, from ($1.41) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About IO Biotech Stock (NASDAQ:IOBT)IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Stock News HeadlinesApril 17, 2024 | msn.comIO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16April 16, 2024 | americanbankingnews.comIO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short InterestApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 15, 2024 | globenewswire.comIO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessApril 11, 2024 | investing.comIO Biotech presents cancer vaccine data at AACRApril 9, 2024 | globenewswire.comIO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103April 5, 2024 | globenewswire.comIO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerMarch 7, 2024 | finance.yahoo.comIO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical TrialsApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 6, 2024 | markets.businessinsider.comBuy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock PositionMarch 6, 2024 | morningstar.comIO Biotech Inc IOBTMarch 6, 2024 | msn.comIO Biotech GAAP EPS of -$0.40 misses by $0.02March 6, 2024 | globenewswire.comIO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 5, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023March 5, 2024 | globenewswire.comIO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsFebruary 26, 2024 | globenewswire.comIO Biotech to Present at 44th Annual Cowen Health Care ConferenceFebruary 4, 2024 | msn.comWhat's Next for Iovance Biotherapeutics Stock?January 15, 2024 | finance.yahoo.comIO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%January 3, 2024 | seekingalpha.comIO Biotech: A Phase 3 Company Getting No RespectDecember 21, 2023 | finance.yahoo.comIO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDecember 19, 2023 | finance.yahoo.comWe're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateNovember 27, 2023 | msn.comIO Biotech executive discloses purchase of 10K sharesNovember 24, 2023 | seekingalpha.comIOBT IO Biotech, Inc.November 15, 2023 | investing.comIO Biotech earnings beat, revenue was in line with estimatesNovember 15, 2023 | markets.businessinsider.comPromising Clinical Trials and Favorable Safety Profile Drives Buy Rating for IO BiotechNovember 14, 2023 | benzinga.comIO Biotech Stock (NASDAQ:IOBT) Earnings Dates and Earning CallsNovember 13, 2023 | msn.comIO Biotech GAAP EPS of -$0.43 misses by $0.10See More Headlines Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+478.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.28% Return on Assets-59.61% Debt Debt-to-Equity RatioN/A Current Ratio9.37 Quick Ratio9.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.71Miscellaneous Outstanding Shares65,880,000Free Float63,575,000Market Cap$94.87 million OptionableNot Optionable Beta0.49 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 56)Founder, President, CEO, Principal Financial Officer & Director Comp: $733.88kMs. Amy B. Sullivan M.B.A. (Age 54)Chief Financial Officer Comp: $391.24kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen M.D.Ph.D., Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMr. Eric Faulkner M.B.A.Chief Technical OfficerMr. Devin Whittemore Smith (Age 56)Secretary, General Counsel & Chief Compliance Officer Mr. Daniel G. Mannix Ph.D.Senior Vice President of Regulatory AffairsDr. Qasim Iftikhar Ahmad M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsCartesian TherapeuticsNASDAQ:RNACAnixa BiosciencesNASDAQ:ANIXEmergent BioSolutionsNYSE:EBSPDS BiotechnologyNASDAQ:PDSBBarinthus BiotherapeuticsNASDAQ:BRNSView All CompetitorsInsiders & InstitutionsPFM Health Sciences LPBought 987,654 shares on 2/15/2024Ownership: 3.554%Armistice Capital LLCSold 224,000 shares on 2/13/2024Ownership: 2.920%Stonepine Capital Management LLCSold 309,271 shares on 2/13/2024Ownership: 2.529%Holdings A/S NovoSold 658,809 sharesTotal: $988,213.50 ($1.50/share)Brian BurkavageBought 5,000 shares on 11/21/2023Total: $4,950.00 ($0.99/share)View All Insider TransactionsView All Institutional Transactions IOBT Stock Analysis - Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks. What is IO Biotech's stock price target for 2024? 3 Wall Street research analysts have issued 12 month target prices for IO Biotech's shares. Their IOBT share price targets range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.33 in the next year. This suggests a possible upside of 478.7% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts. How have IOBT shares performed in 2024? IO Biotech's stock was trading at $1.88 at the beginning of the year. Since then, IOBT stock has decreased by 23.4% and is now trading at $1.44. View the best growth stocks for 2024 here. Are investors shorting IO Biotech? IO Biotech saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 68,200 shares, a decrease of 16.4% from the March 15th total of 81,600 shares. Based on an average daily volume of 138,300 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.2% of the shares of the stock are short sold. View IO Biotech's Short Interest. When is IO Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IOBT earnings forecast. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOBT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
